It isnt every day that traders cut one of the FTSE 100s blue chips in half.
That plunge in Micro Focus Internationals shares
during the past week made Facebooks
selloff look mild. The Micro Focus bullsthey still existview the dive as overdone. They snort that the British business-software company boasts several stable revenue streams and a healthy balance sheet.
Top Blue Chip Stocks To Buy Right Now: Aphria Inc. (APHQF)
- [By Javier Hasse]
Check out Part 2 of this article, where Phillips shares a look at some other notable transactions announced last week, featuring Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), Aphria Inc (OTC: APHQF), Invictus MD (OTC: IVITF) and more.
- [By Todd Campbell]
While some marijuana companies are turning a profit, many marijuana companies are investing heavily in their businesses, and as a result, continue to lose money. For example, Aphria Inc. (NASDAQOTH:APHQF), a Canadian producer and marketer of medical marijuana, reported a net profit of $1 million over the past 12 months, but medical-marijuana drug developer GW Pharmaceuticals plc (NASDAQ:GWPH) reported a loss of $82.2 million last fiscal year.
- [By Sean Williams]
This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.
GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%
As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!
Top Blue Chip Stocks To Buy Right Now: AirMedia Group Inc(AMCN)
- [By Paul Ausick]
AirMedia Group Inc. (NASDAQ: AMCN) posted a 52-week low of $1.04 after closing down 23% on Wednesday at $1.35. The 52-week high is $3.30. Volume was about 4 million, nearly 20 times the daily average of around 230,000 million shares. The Chinese outdoor advertising company said yesterday that it is terminating a potential go-private transaction.
Top Blue Chip Stocks To Buy Right Now: Calumet Specialty Products Partners L.P.(CLMT)
- [By Lisa Levin]
In trading on Friday, energy shares tumbled by 1.25 percent. Meanwhile, top losers in the sector included Southwestern Energy Company (NYSE: SWN), down 16 percent, and Calumet Specialty Products Partners, L.P (NASDAQ: CLMT), down 14 percent.
- [By Lisa Levin]
In trading on Friday, energy shares fell 1.02 percent. Meanwhile, top losers in the sector included Whiting Petroleum Corp (NYSE: WLL), down 8 percent, and Calumet Specialty Products Partners, L.P (NASDAQ: CLMT) down 7 percent.
- [By Lisa Levin]
Calumet Specialty Products Partners, L.P (NYSE: CLMT) was down, falling around 9 percent to $7.65. Janney Capital downgraded Calumet Specialty from Buy to Neutral.
Top Blue Chip Stocks To Buy Right Now: ZELTIQ Aesthetics, Inc.(ZLTQ)
- [By James E. Brumley]
This week, Botox maker Allergan plc (NYSE:AGN) shelled out $2.5 billion for body-sculpting outfit Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). The pairing is a nice opportunity for both organizations to cross-sell to one another’s customers. Allergan’s Botox customers seeking a more youthful face will also likely want the better body Zeltiq Aesthetics provides, and Zeltiq Aesthetics’ customers are natural candidates for Botox injections that Allergan facilitates.
The acquisition, though, is just a microcosm of a bigger trend that’s still picking up steam. That trend is, as the industry’s capabilities to restore youth, slim waists, whiten teeth, improve skin, and nip and tuck here and there improve with science, demand for these increasingly effective ‘tweaks’ is soaring. Names like the aforementioned Allergan, Cynosure, Inc. (NASDAQ:CYNO), Zeltiq Aesthetics and Align Technology, Inc. (NASDAQ:ALGN) are all driving impressive growth. And, they’re all looking to expand their footprint in front of the rising tide.
Not every name riding this growth wave is going to be a large cap stock or a household name though. There’s a small cap stock called RepliCel Life Sciences (OTCMKTS:REPCF, CVE:RP) that could soon be turning a lot of heads not just of investors, but of potential suitors.
In simplest terms, RepliCel Life Sciences has two key sciences that serve as the foundation for three therapies and one medical device.
The first of the two biological premises is based on the company’s non-bulbar dermal sheath fibroblast platform, and currently includes treatments for chronic tendinosis and skin aging. The second is the company’s dermal sheath cup (DSC) cell platform for the treatment of androgenetic alopecia (pattern baldness).
The three marketable products those two sciences are driving are RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair regeneration. The device is a dermal injector – currently categorized as R